FDA Panel Backs Wider Access to Six Peptide Therapies, Citing Grey...

shared a link

2026-07-29 07:00:06

FDA Panel Backs Wider Access to Six Peptide Therapies, Citing Grey Market Concerns

A Food and Drug Administration (FDA) advisory panel has voted to recommend expanding legal access to six popular peptide compounds. Supporters say could pull patients out of the unregulated grey market

0 Comments 0 Shares 31 Views